Physician profile
Masako Chen
NPI 1316309867
$1,999.86
in general payments reported to CMS, 2019-2025
15 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $234 · 2021: $718 · 2022: $30.71 · 2023: $204 · 2024: $227 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $898.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $648.82 | 2020-2023 | Clareon |
| Glaukos Corporation | $379.98 | 2020-2025 | Idosetr |
| Dompe US, INC. | $247.66 | 2021-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $247.17 | 2021 | |
| Omeros Corporation | $118.37 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $59.60 | 2024 | Tecnis Simplicity |
| Apellis Pharmaceuticals, INC. | $57.31 | 2024-2025 | Syfovre |
| Oyster Point Pharma, INC. | $50.90 | 2023-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $42.58 | 2024 | Xdemvy |
| Recordati_rare_diseases_inc. | $31.79 | 2021 | |
| Bausch & Lomb Americas INC. | $30.71 | 2022 | |
| Sun Pharmaceutical Industries INC. | $26.58 | 2024 | |
| Sight Sciences, INC. | $25.01 | 2023 | Tearcare System |
| Rxsight INC | $19.67 | 2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Amgen INC. | $13.71 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Masako Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.